- For evaluation of drugs and screening potential inhibitors of α-amylase.
- Safe. Non-radioactive assay.
- Fast and convenient. Homogeneous “mix-incubate-measure” type assay. Can be completed in under an hour at room temperature.
- Robust and High-throughput. A Z’-factor of >0.90 was observed in a 384-well format. Can be readily automated to assay thousands of samples per day.
- FP485/520 nm
- Compounds that affect α-amylase activity
- 40 min
- 400 tests in 384-well plate
- 6 months
AMYLASE belongs to the family of glycoside hydrolase enzymes that break down starch into glucose molecules by acting on α-1,4-glycosidic bonds. The α-amylases (EC 184.108.40.206) cleave at random locations on the starch chain, ultimately yielding maltotriose and maltose, glucose and “limit dextrin” from amylose and amylopectin. In mammals, α-amylase is a major digestive enzyme. Increased enzyme levels in humans are associated with salivary trauma, mumps due to inflammation of the salivary glands, pancreatitis and renal failure.
Simple, direct and automation-ready procedures for measuring α-amylase inhibition are highly desirable in Research and Drug Discovery. BioAssay Systems’ QuantiFluo™ α-Amylase Inhibitor Screening Kit utilizes fluorescence polarization (FP) to screen for potential α-amylase inhibitors. In this assay, α-amylase cleaves a fluorescent amylose substrate. The decrease in FP is directly proportional to the α-amylase activity in the sample. Inhibition is therefore determined by the increase in FP (λex/em = 485/520 nm).